Slide 1: Atomo Diagnostics (ASX:AT1)
ATOMO DIAGNOSTICS (ASX:AT1)
Slide 2: Executive Summary
EXECUTIVE SUMMARY Atomo Diagnostics Limited is an innovative medical device diagnostics company supplying unique, integrated rapid diagnostic test devices and finished point-of-care rapid tests to global partners and consumers Atomo is a global company headquartered in Australia with commercial reso
Slide 3: Who is Atomo and what does it do?
WHO IS ATOMO AND WHAT DOES IT DO? Atomo’s portfolio of tests and technologies allows people to test early and test often, putting healthcare in the hands of the consumer WHO IS ATOMO? WHAT DO WE DO? Headquartered in Australia and listed on the ASX, Atomo Atomo’s strategic focus is on two revenue gen
Slide 4: Atomo leads disruptive innovation in rapid testing
ATOMO LEADS DISRUPTIVE INNOVATION IN RAPID TESTING Atomo has developed best-in-class rapid tests that transform ease of use and reliability “I would rather pay for this test in future (than use a free test) if it “The lancet would not be out of place in a Christmas cracker” means it is this easy” Ho
Slide 5: Drivers of the adoption of rapid testing
DRIVERS OF THE ADOPTION OF RAPID TESTING Adoption of decentralised testing driven by ease of use, speed and accessibility 1 WHAT DRIVES ADOPTION OF RAPID TESTING ATOMO’S PASCAL DEVICE VS. COMPETITORS An independent study was conducted to validate Atomo’s Pascal device usability when compared to a st
Slide 6: Atomo's HIV self test commercialised and sold globally
ATOMO’S HIV SELF TEST COMMERCIALISED AND SOLD GLOBALLY Atomo has developed and successfully launched the world’s first integrated, blood-based HIV Self Test which is now registered in 46 countries with over 1.5 million units sold* With regulatory Finished product Contract signed with HIV self-testin
Slide 7: Future product roadmap
FUTURE PRODUCT ROADMAP Atomo has a strong pipeline of product development moving beyond infectious diseases to target women’s health and at-home wellness monitoring 2023/24 2024 AND BEYOND PREGNANCY FERRITIN VITAMIN D & OTHERS Atomo and partner NG Biotech have developed a Atomo is commercialising a
Slide 8: Pregnancy market opportunity
PREGNANCY MARKET OPPORTUNITY Atomo’s early detection pregnancy test has a material opportunity to create a premium niche in the valuable female healthcare market 1 2 GLOBAL PREGNANCY TESTING MARKET SIZE (REVENUE AUD ) ATOMO’S OPPORTUNITY Atomo has experience in expanding distribution partnerships ac
Slide 9: AtomoNOW Pregnancy Test
ATOMONOW™ PREGNANCY TEST TM The AtomoNOW™ Pregnancy Test is the only blood-based pregnancy test on the Australian 1 market BENEFITS hCG levels build up earlier in blood than in urine, making blood a better sample type for early detection of pregnancy Extensive clinical studies show a high accuracy r
Slide 10: Atomo's business: de-risked, validated and scaling
ATOMO’S BUSINESS: DE-RISKED, VALIDATED AND SCALING PRODUCT RISK REVENUE / SALES RISK MARKET RISK REGULATORY RISK STATUS STATUS STATUS STATUS Designed to address user challenges Increasing HIV test sales, existing OEM Key stakeholders now support home testing Class IV (highest) approvals in place for
Slide 11: The home test market - responding to consumer demand
THE HOME TEST MARKET - RESPONDING TO CONSUMER DEMAND New and incumbent industry players increasingly focused on at-home consumer test market Consumer-Initiated Testing $250M Revenues by 2025 * The slide depicts general examples, not only specific Atomo Diagnostics products, customers or channels ATO
Slide 12: Key metrics
KEY METRICS Annual Revenue (Inc. COVID-19) Early revenue from first commercialisation of HIV Self Tests in 15.00 the South African domestic market in FY19 12.00 $M AUD Non-COVID revenue growth impacted during FY20-FY22 by 9.00 diversion of funding and attention to COVID-19 testing 6.00 3.00 Pivot to
Slide 13: Key investment highlights
KEY INVESTMENT HIGHLIGHTS Atomo operates in an expanding global rapid testing market driven by significant industry and consumer tailwinds 1 2 Atomo has patent protected user friendly testing technology, with multiple OEM contracts, a strong pipeline and emerging channel partner demand Best-in-class
Slide 14: Capital raising structure
CAPITAL RAISING STRUCTURE Placement to raise approximately $1.25 million under the company’s existing placement capacity per LR7.1 (“Placement”) Placement Approximately 35.0 million new fully paid ordinary shares in AT1 (“New Shares”) to be issued under the Placement, representing approximately 6.1%
Slide 15: Use of funds
USE OF FUNDS Atomo’s focus is on expanding and accelerating its sales, marketing, business development and new product registration activities to focus on revenue generating activities and growth. The primary objectives are: USE OF FUNDS $ Commencement of the FDA registration process for the hCG Pre
Slide 16: Timetable
TIMETABLE 1 EVENT 2023 Record Date for the SPP 7.00pm Wednesday, 12 July 2023 Capital Raising announced and trading halt lifted Thursday, 13 July 2023 SPP Offer opens Tuesday, 18 July 2023 Settlement of the Placement Tuesday, 18 July 2023 Allotment of New Shares under the Placement Wednesday, 19 Jul
Slide 17: Disclaimer
DISCLAIMER This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on made available to the recipient in connection with the opportunity outlined in this presentation and information available as at the date of this presentation. The information in this presentation is no re